Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors

Bioorg Med Chem. 2004 Mar 1;12(5):1129-39. doi: 10.1016/j.bmc.2003.11.034.

Abstract

New imidazo[1,2-a]quinoxaline derivatives have been synthesised by condensation of an appropriate alpha-aminoalcohol with a quinoxaline followed by intramolecular cyclisation and nucleophilic substitutions. Their phosphodiesterase inhibitory activities have been assessed on a preparation of the PDE4 isoform purified from a human alveolar epithelial cell line (A549). These studies showed potent inhibitory properties that emphasize the importance of a methyl amino group at position 4 and a weakly hindered group at position 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • 3',5'-Cyclic-AMP Phosphodiesterases / isolation & purification
  • Cell Line
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Drug Design
  • Epithelial Cells / enzymology
  • Humans
  • Inflammation / prevention & control
  • Inhibitory Concentration 50
  • Lung / cytology
  • Quinoxalines / chemical synthesis*
  • Quinoxalines / pharmacology*
  • Structure-Activity Relationship

Substances

  • Quinoxalines
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4